Pre-market Hot Trades in US Stocks

Clps fell 8.49% in pre-market trading. There has been no significant news recently; trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news

NetEase rose 7.14% in pre-market trading. Based on recent key news:

1. On August 20, NetEase announced its Q2 2026 financial report, with net revenue of 30.1 billion yuan, a year-on-year increase of 7.9%, exceeding market expectations. Strong performance in gaming revenue drove the stock price up. Source: Zhitong Finance

2. On August 21, Citigroup released a report maintaining a "Buy" rating on NetEase and raised its US stock target price to $178 due to strong gaming revenue. Source: Zhitong Finance

3. On August 21, Bank of America Securities raised its target price for NetEase to HKD 272 and reiterated its "Buy" rating due to record high gaming gross margins. Source: Zhitong Finance. The overall performance of the gaming industry is strong, supported by policies.

Top Gainers in Pre-market US Stocks

RF Acquisition Corp II rose 405.81% in pre-market trading. Based on recent key news:

1. On August 19, shareholders of RF Acquisition Corp II approved the business merger plan with Nanyang Biologics. The advancement of this transaction significantly boosted the company's stock price, with The9 expected to hold 15% to 16% of the merged company.

2. On August 20, RF Acquisition Corp II released a related announcement through the EDGAR system, further confirming the progress of the transaction and enhancing market confidence.

3. On August 21, investors submitted preliminary redemption requests for 3.95 million shares. Although the final redemption numbers have not been confirmed, this dynamic shows the market's attention to the company's future development. The market is optimistic about the merger transaction, driving the stock price up.

Werewolf Therapeutics rose 130.43% in pre-market trading. Based on recent key news:

1. On August 20, Werewolf Therapeutics announced the sale of its inducers and Indukine platform to EMD Serono. According to SEC filings, EMD will pay a $28 million upfront payment and an additional $5 million upon completion of the asset transfer. This transaction provided the company with funding support, significantly boosting the stock price.

2. On August 20, Werewolf Therapeutics obtained exclusive development licenses for WTX-124 and WTX-330 from EMD. This licensing agreement secures the company's future R&D and enhances market confidence in its growth potential, further driving up the stock price. The biotechnology industry has seen active trading recently, with significant capital inflows RF ACQUISITION CORP II COM USD0.0001 (S/R 15/02/2027) pre-market rose 85.27%, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation